P H Jones

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    Peter H Jones
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 95:120-2. 2005
  2. ncbi request reprint Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
  3. ncbi request reprint Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 26:1388-99. 2004
  4. ncbi request reprint Statins: the case for higher, individualized starting doses
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX, USA
    Cleve Clin J Med 72:811-6. 2005
  5. ncbi request reprint Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options
    Peter H Jones
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 148:S9-13. 2004
  6. ncbi request reprint Rationale for intensive statin treatment in high-risk patients
    Peter H Jones
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX 77030, USA
    Prev Cardiol 9:91-5. 2006
  7. ncbi request reprint Dyslipidemia in older adults
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Geriatr Cardiol 15:239-44. 2006
  8. pmc Lipids: new guidelines, intensive treatment, and future directions
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, and Methodist Wellness Center for Weight Management, Houston, Texas 77030, USA
    Tex Heart Inst J 33:180-3. 2006
  9. doi request reprint Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Am Heart J 160:759-66. 2010
  10. ncbi request reprint Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme
    Peter H Jones
    Baylor College of Medicine, Houston, Texas, USA
    Clin Drug Investig 28:625-34. 2008

Detail Information

Publications51

  1. ncbi request reprint Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    Peter H Jones
    Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 95:120-2. 2005
    ..The findings suggest that the use of fenofibrate in combination with statins results in fewer reports of rhabdomyolysis per million prescriptions dispensed than does the use of gemfibrozil...
  2. ncbi request reprint Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  3. ncbi request reprint Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 26:1388-99. 2004
    ....
  4. ncbi request reprint Statins: the case for higher, individualized starting doses
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, TX, USA
    Cleve Clin J Med 72:811-6. 2005
    ....
  5. ncbi request reprint Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options
    Peter H Jones
    Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 148:S9-13. 2004
    ....
  6. ncbi request reprint Rationale for intensive statin treatment in high-risk patients
    Peter H Jones
    Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX 77030, USA
    Prev Cardiol 9:91-5. 2006
    ..Results of recent clinical and surrogate end point trials confirm that intensive lowering of low-density lipoprotein cholesterol is beneficial and safe in a majority of high-risk patients...
  7. ncbi request reprint Dyslipidemia in older adults
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Geriatr Cardiol 15:239-44. 2006
    ....
  8. pmc Lipids: new guidelines, intensive treatment, and future directions
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, and Methodist Wellness Center for Weight Management, Houston, Texas 77030, USA
    Tex Heart Inst J 33:180-3. 2006
  9. doi request reprint Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Am Heart J 160:759-66. 2010
    ..Statin and ezetimibe combination therapy may be insufficient to improve lipid and nonlipid parameters beyond low-density lipoprotein cholesterol (LDL-C) in patients with mixed dyslipidemia...
  10. ncbi request reprint Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme
    Peter H Jones
    Baylor College of Medicine, Houston, Texas, USA
    Clin Drug Investig 28:625-34. 2008
    ..A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid...
  11. doi request reprint Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Atherosclerosis 204:208-15. 2009
    ..To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia...
  12. ncbi request reprint Treating dyslipidemia in the high-risk patient
    Peter H Jones
    Lipid Metabolism and Atherosclerosis Clinic, Baylor College of Medicine, Houston, TX, USA
    J Fam Pract 59:E1. 2010
    ..While LDL-cholesterol remains the primary target for coronary heart disease prevention, non-HDL-cholesterol is an important secondary target in patients with mixed dyslipidemia...
  13. doi request reprint Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials
    Peter H Jones
    Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiovasc Drugs 10:73-84. 2010
    ..Monotherapy with lipid-modifying medication is frequently insufficient to normalize lipid abnormalities in patients with mixed dyslipidemia and type 2 diabetes mellitus...
  14. ncbi request reprint Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    P H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs 59:1127-35. 2000
    ..94 mmol/L). These trials have sufficient patient numbers and power to definitely determine if reducing LDL-C levels to approximately 75 mg/dl can provide an acceptable benefit-to-risk-ratio...
  15. doi request reprint Achieving cholesterol goals. Current and future drug therapies
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Postgrad Med 114:14-21. 2003
    ..The statins can be used alone, or in combination with a bile acid sequestrant, ezetimibe, or niacin in patients with mixed dyslipidemias...
  16. ncbi request reprint Comparing HMG-CoA reductase inhibitors
    Peter H Jones
    Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cardiol 26:I15-20. 2003
    ..The possibility that statins exert pronounced effects beyond lowering blood lipids is opening other avenues of research into the benefits of these drugs...
  17. doi request reprint The power of statins: aggressive lipid lowering
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Postgrad Med 112:23-30. 2002
    ..In the past, choices for pharmacotherapeutic intervention were limited by issues of tolerance and, therefore, patient compliance. Fortunately, the statin class of drugs offer lipid lowering with both good safety and tolerability...
  18. doi request reprint Cholesterol and coronary events. The current thinking
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Postgrad Med 113:5-14. 2003
    ..Statins effectively reduce the components of non-HDL-C, and some members produce elevations in HDL-C approaching those achieved with fibrates. Accordingly, statin therapy is appropriate for a wide range of dyslipidemic patients...
  19. ncbi request reprint Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Tex 77030, USA
    Am Heart J 149:e1. 2005
    ..The NASDAC study was designed to evaluate the safety and efficacy of atorvastatin at starting doses of 10, 20, 40, and 80 mg...
  20. ncbi request reprint Effects of lipid lowering therapy on progression of coronary and carotid artery disease
    C M Ballantyne
    Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Lipidol 8:354-61. 1997
    ..Angiographic and arterial ultrasound trials of lipid lowering therapy have demonstrated benefits on disease progression that are consistent with benefits on myocardial infarction, stroke, and death reported in larger, lengthier trials...
  21. ncbi request reprint Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus
    Peter H Jones
    Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Cardiol 99:133B-140B. 2007
    ..It is hoped that ongoing trials will demonstrate the clinical outcomes benefits of combination therapy in patients with diabetes...
  22. ncbi request reprint Safety of statins: effects on muscle and the liver
    Abu R Vasudevan
    Division of Endocrinology and Metabolism, Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Cleve Clin J Med 72:990-3, 996-1001. 2005
    ....
  23. ncbi request reprint Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
    C M Ballantyne
    Baylor College of Medicine, Houston, Tex 77030, USA
    Circulation 99:736-43. 1999
    ..CONCLUSIONS--Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit...
  24. ncbi request reprint US with extended field of view: phantom-tested accuracy of distance measurements
    B D Fornage
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiology 214:579-84. 2000
    ..4% (537 of 540) of the distance measurements were accurate within plus or minus 4%. This extended-FOV technology provides accurate measurements of large objects in vitro...
  25. ncbi request reprint Adjunctive interventions in myocardial infarction: the role of statin therapy
    Peter H Jones
    Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Room 525D, Houston, TX 77030, USA
    Curr Atheroscler Rep 10:142-8. 2008
    ....
  26. pmc Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination
    Ryan C Neal
    Baylor College of Medicine, Section of Lipid and Atherosclerosis, Houston, TX 77030, USA
    Vasc Health Risk Manag 2:31-8. 2006
    ..One of these newer therapies is the combination of ezetimibe and simvastatin. This article reviews the implications of the updated guidelines and discusses the efficacy and safety of ezetimibe/simvastatin for lowering LDL-C...
  27. ncbi request reprint Lipid-lowering: can ezetimibe help close the treatment gap?
    Ryan C Neal
    Baylor College of Medicine, Houston, Texas 77030, USA
    Cleve Clin J Med 70:777-83. 2003
    ..Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin...
  28. ncbi request reprint Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trial
    Michael Fordis
    Center for Collaborative and Interactive Technologies, Department of Pediatrics, Baylor College of Medicine, Houston, Tex 77030, USA
    JAMA 294:1043-51. 2005
    ....
  29. ncbi request reprint Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia
    Antonios M Xydakis
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, 6565 Fannin Street, Houston, TX 77030, USA
    Am J Cardiol 94:795-7. 2004
    ..03), without significantly changing high-density lipoprotein cholesterol, and the combination was well tolerated...
  30. ncbi request reprint Effective use of combination lipid therapy
    Abu R Vasudevan
    Center for Cardiovascular Disease Prevention, Lipid and Atherosclerosis Section, Baylor College of Medicine, 6565 Fannin, Suite B160A, MS A601, Houston, TX 77030, USA
    Curr Cardiol Rep 7:471-9. 2005
    ..Careful surveillance of hepatic transaminases, avoidance of gemfibrozil in statin-fibrate combinations, and awareness of statin-concomitant drug interactions is key to safe and efficacious use of combination lipid drug therapy...
  31. ncbi request reprint Toxicity of antilipidemic agents: facts and fictions
    Antonios M Xydakis
    Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Houston, TX 77030, USA
    Curr Atheroscler Rep 5:403-10. 2003
  32. ncbi request reprint The use of statins in acute coronary syndromes: the mechanisms behind the outcomes
    J C Plana
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, 6565 Fannin, RM B564, M S B501, Houston, TX 77030 2707, USA
    Curr Atheroscler Rep 3:355-64. 2001
    ..This review examines these effects of statins and lipoproteins on vascular function, as well as the clinical evidence supporting early treatment in acute coronary syndromes...
  33. ncbi request reprint Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system
    Mine Y Liu
    Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Chem 51:1102-9. 2005
    ..This study focuses on multiplexed analyses of adipocytokines and biomarkers linked to the metabolic syndrome, diabetes, and cardiovascular disease...
  34. ncbi request reprint Atherosclerosis target of lipid-lowering therapy: is lower LDL cholesterol better?
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, USA
    Am J Manag Care . 2003
  35. ncbi request reprint Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'
    Ashok Balasubramanyam
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Lipidol 15:59-67. 2004
    ..Identification of rationally based therapies requires an understanding of the mechanistic basis of HADL...
  36. pmc CD11c expression in adipose tissue and blood and its role in diet-induced obesity
    Huaizhu Wu
    Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
    Arterioscler Thromb Vasc Biol 30:186-92. 2010
    ..To examine CD11c, a beta(2)-integrin, on adipose tissue (AT) leukocytes and blood monocytes and its role in diet-induced obesity...
  37. ncbi request reprint Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Am J Med 116:17S-25S. 2004
    ..The increasing focus on intensive plasma lipid lowering to reduce CHD risk has placed a premium on the development of therapies with improved ability to reduce plasma levels of LDL-C...
  38. ncbi request reprint Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction
    Antonios M Xydakis
    Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 89:2697-703. 2004
    ..Thus, increases in plasma levels of adiponectin or reductions in TNF-alpha are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss...
  39. ncbi request reprint The editor's roundtable: concurrent hypertension and dyslipidemia
    Vincent E Friedewald
    University of Texas Health Sciences Center at Houston, Houston, TX, USA
    Am J Cardiol 99:134-44. 2007
  40. ncbi request reprint Eotaxin and obesity
    Abu R Vasudevan
    Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 91:256-61. 2006
    ..Asthma and obesity incidence is increasing worldwide, and asthma is often more severe in the obese. Eotaxin, a CC chemokine, is important in extrinsic asthma, an inflammatory disorder...
  41. ncbi request reprint Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
    Prakash C Deedwania
    VA Central California Health Care System and University of California San Francisco, Fresno, California, USA
    Am J Cardiol 95:360-6. 2005
    ..Rosuvastatin had the most favorable effect on the atherogenic lipid profile of MS overall...
  42. doi request reprint Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels
    Masumi Ai
    Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University, Boston, Massachusetts, USA
    Am J Cardiol 101:315-8. 2008
    ....
  43. ncbi request reprint Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia
    Nicole E Jelesoff
    Department of Medicine, Division of Endocrinology, Nutrition, and Metabolism, Duke University Medical Center, Durham, North Carolina 27710, USA
    Endocr Pract 12:159-64. 2006
    ..To determine the effectiveness and tolerability of adding ezetimibe, 10 mg daily, to niacin-based regimens for dyslipidemia...
  44. ncbi request reprint Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial
    James M McKenney
    National Clinical Research, Richmond, Virginia, USA
    Curr Med Res Opin 19:689-98. 2003
    ..0 mmol/l [< 266 mg/dl] to < 2.0 mmol/l [< 177 mg/dl]), and the total cholesterol/high-density lipoproteincholesterol ratio (< 4 to < 7) (70% to 83% versus 35% to 79%)...
  45. ncbi request reprint Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
    James M McKenney
    National Clinical Research, Richmond, VA 23227, United States
    Atherosclerosis 192:432-7. 2007
    ..No drug-related myopathy or hepatotoxicity was observed. In this study, low to moderate dose combination therapy with a statin and niacin ER provided broad control of lipids and lipoproteins independently associated with CHD...
  46. ncbi request reprint Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins
    Bela F Asztalos
    Cardiovascular Research Laboratory, Tufts University, Boston, Massachusetts, USA
    Am J Cardiol 99:681-5. 2007
    ..In conclusion, our data show that both statins, given at their maximal doses, favorably alter the HDL subpopulation profile, but also that rosuvastatin is significantly more effective in this regard than atorvastatin...
  47. ncbi request reprint Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker
    Marshall A Corson
    Division of Cardiology, Department of Medicine, University of Washington, 325 9th Avenue, Seattle, WA 98104, USA
    Am J Cardiol 101:41F-50F. 2008
    ..Ultimately, Lp-PLA(2) may also be classified as a risk factor, but this should not detract from its utility today as a risk marker...
  48. pmc Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Vasc Health Risk Manag 3:733-42. 2007
    ..Finally this paper specifically reviews colesevelam HCl's pharmacology, lipid and glucose efficacy, safety/tolerability, and clinical use...
  49. ncbi request reprint Statin therapy: is the percent reduction or the attained low-density lipoprotein cholesterol level more important?
    Tracie C Collins
    Division of General Internal Medicine, University of Minnesota, 420 Delaware Street SE, MMC 451, Minneapolis, MN 55455, USA
    Curr Atheroscler Rep 9:10-7. 2007
    ..In this review article, we discuss the role of percent LDL-C reduction versus attained LDL-C levels as targets for statin therapy in order to maximize the preventive care provided to high-risk patients...
  50. ncbi request reprint The metabolic syndrome and type 2 diabetes: role of the adipocyte
    Ruth McPherson
    Curr Opin Lipidol 14:549-53. 2003
  51. ncbi request reprint Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines
    Michael H Davidson
    Preventive Cardiology Center, Pritzker School of Medicine, University of Chicago, 515 North State Street, Chicago, IL 60610, USA
    Am J Cardiol 101:51F-57F. 2008
    ..However, at this time Lp-PLA(2) cannot be recommended as a target of therapy...